Current insights and assumptions on α-synuclein in Lewy body disease
Acta Neuropathologica · 14.08.2024 · 148 (1)
DOI: 10.1007/s00401-024-02781-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Neuropathologica, online erschienen am 14.08.2024. Verfasst von Rehana K Leak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Duquesne University, 418C Mellon Hall, 913 Bluff Street, Pittsburgh, PA, 15219, USA. leakr@duq.edu. Hauptthemen laut MEDLINE: Lewy Body Disease, alpha-Synuclein. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 279 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIGMS NIH HHS, BLRD VA.
Abstract (Originalsprache)
Lewy body disorders are heterogeneous neurological conditions defined by intracellular inclusions composed of misshapen α-synuclein protein aggregates. Although α-synuclein aggregates are only one component of inclusions and not strictly coupled to neurodegeneration, evidence suggests they seed the propagation of Lewy pathology within and across cells. Genetic mutations, genomic multiplications, and sequence polymorphisms of the gene encoding α-synuclein are also causally linked to Lewy body disease. In nonfamilial cases of Lewy body disease, the disease trigger remains unidentified but may range from industrial/agricultural toxicants and natural sources of poisons to microbial pathogens. Perhaps due to these peripheral exposures, Lewy inclusions appear at early disease stages in brain regions connected with cranial nerves I and X, which interface with inhaled and ingested environmental elements in the nasal or gastrointestinal cavities. Irrespective of its identity, a stealthy disease trigger most likely shifts soluble α-synuclein (directly or indirectly) into insoluble, cross-β-sheet aggregates. Indeed, β-sheet-rich self-replicating α-synuclein multimers reside in patient plasma, cerebrospinal fluid, and other tissues, and can be subjected to α-synuclein seed amplification assays. Thus, clinicians should be able to capitalize on α-synuclein seed amplification assays to stratify patients into potential responders versus non-responders in future clinical trials of α-synuclein targeted therapies. Here, we briefly review the current understanding of α-synuclein in Lewy body disease and speculate on pathophysiological processes underlying the potential transmission of α-synucleinopathy across the neuraxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Duquesne University, 418C Mellon Hall, 913 Bluff Street, Pittsburgh, PA, 15219, USA. leakr@duq.edu.
- Graduate School of Pharmaceutical Sciences, Duquesne University, 418C Mellon Hall, 913 Bluff Street, Pittsburgh, PA, 15219, USA.
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
- Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Pennsylvania, PA, USA.
ORCID-Profile: Rehana K Leak
Förderung
- NINDS NIH HHS
- NIGMS NIH HHS
- BLRD VA
- National Institute of Neurological Disorders and Stroke
- National Institute of General Medical Sciences
Zitieren
APA
Leak, R. K., Clark, R. N., Abbas, M., Xu, F., Brodsky, J. L., Chen, J., Hu, X., & Luk, K. C. (2024). Current insights and assumptions on α-synuclein in Lewy body disease. Acta Neuropathologica, 148(1). https://doi.org/10.1007/s00401-024-02781-3
Vancouver
Leak RK, Clark RN, Abbas M, Xu F, Brodsky JL, Chen J, et al. Current insights and assumptions on α-synuclein in Lewy body disease. Acta Neuropathologica. 2024;148(1). doi:10.1007/s00401-024-02781-3
BibTeX
@article{Leak2024,
author = {Leak, Rehana K and Clark, Rachel N and Abbas, Muslim and Xu, Fei and Brodsky, Jeffrey L and Chen, Jun and Hu, Xiaoming and Luk, Kelvin C},
title = {Current insights and assumptions on α-synuclein in Lewy body disease},
journal = {Acta Neuropathologica},
year = {2024},
volume = {148},
number = {1},
doi = {10.1007/s00401-024-02781-3}
}
EUVIMED